Shape Therapeutics is a biotechnology company focused on developing breakthrough RNA technologies to shape the future of gene therapy.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/15/2021 | Series B | $112MM | $xx.xx | $49.36B | Breton Capital, Decheng Capital, Mission Biocapital, New Enterprise Associates, Willett Advisors | |
Price per Share
$xx.xx
Shares Outstanding
56,899,958
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Breton Capital, Decheng Capital, Mission Biocapital, New Enterprise Associates, Willett Advisors
|
||||||
11/05/2019 | Series A-1 | $13.33MM | $xx.xx | $14.31B | Cureduchenne Ventures, Mission Biocapital, New Enterprise Associates, Tectonic Capital | |
Price per Share
$xx.xx
Shares Outstanding
44,999,982
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cureduchenne Ventures, Mission Biocapital, New Enterprise Associates, Tectonic Capital
|
||||||
11/05/2019 | Series A-2 | $12.92MM | $xx.xx | $14.31B | Cureduchenne Ventures, Mission Biocapital, New Enterprise Associates, Tectonic Capital | |
Price per Share
$xx.xx
Shares Outstanding
19,373,049
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cureduchenne Ventures, Mission Biocapital, New Enterprise Associates, Tectonic Capital
|